Market Cap 117.45M
Revenue (ttm) 1.63M
Net Income (ttm) -29.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,820.25%
Debt to Equity Ratio 0.00
Volume 312,300
Avg Vol 814,214
Day's Range N/A - N/A
Shares Out 139.40M
Stochastic %K 26%
Beta 0.69
Analysts Strong Sell
Price Target $7.17

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
APRadek
APRadek Sep. 13 at 3:05 PM
$RANI if Form 13G appears following completed and upcoming meetings then ill be adding
0 · Reply
Mandalo
Mandalo Sep. 13 at 7:33 AM
$RANI Form 3 filed, Michelle Gilson has. ​Exercise price: $7.46, it is. ​Holdings: 12,500 option shares, disclosed. ​Director role: Joined the board, she did. Very interesting it is !
3 · Reply
Mandalo
Mandalo Sep. 13 at 7:23 AM
$RANI Connected, Jesper Høiland is. Former Novo Nordisk chief, he was. To Rani Therapeutics, his wisdom now he brings. ​To Rani Therapeutics, joined he has: Head of Strategy, he became. ​From Novo Nordisk, he came: U.S. President, once he was. ​The bridge, he is: Oral RaniPill for obesity and diabetes, push forward he does!
0 · Reply
KaShing01
KaShing01 Sep. 12 at 4:48 PM
$RANI Showing sign of improvements……PT $7.20+
0 · Reply
Mandalo
Mandalo Sep. 12 at 3:23 AM
$RANI In five years, explode Rani Therapeutics' valuation could, hmm. ​From a small $120 million micro-cap today, to a $2.X billion or $5+ billion powerhouse, grow it might. Yes, hrrmm: ​Today small, it is: A cap of $120 million, a mere micro-cap, Rani currently remains. ​The future, bright it shines: In half a decade, transform it will. ​Mighty power, it shall gain: Two billion, five billion, or more, its worth shall become! ​Patience you must have, if market fortunes you seek, yes!
1 · Reply
wavw
wavw Sep. 11 at 7:46 PM
$RANI No one is selling. Shorts need 8 million shares to cover. Some good news will trigger above $5 easily.
1 · Reply
KaShing01
KaShing01 Sep. 11 at 4:37 PM
0 · Reply
French_Vibe
French_Vibe Sep. 11 at 2:27 PM
$RANI could be a good target for a buyout by $HALO IMHO
2 · Reply
OTC85
OTC85 Sep. 11 at 1:35 AM
$RANI https://x.com/ElFonzieMero/status/2091752684432822496
0 · Reply
OTC85
OTC85 Sep. 11 at 1:34 AM
$RANI $ADTX . . https://x.com/ElFonzieMero/status/2091752681102569808
1 · Reply
Latest News on RANI
Rani Therapeutics initiated with a Buy at Chardan

2026-08-18T11:10:37.000Z - 26 days ago

Rani Therapeutics initiated with a Buy at Chardan


Rani Therapeutics reports Q2 EPS (4c), consensus (5c)

2026-08-16T14:06:16.000Z - 4 weeks ago

Rani Therapeutics reports Q2 EPS (4c), consensus (5c)


Rani Therapeutics Holdings Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Rani Therapeutics Holdings Earnings release: Q2 2026


Rani Therapeutics Holdings Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Rani Therapeutics Holdings Quarterly report: Q2 2026


Rani Therapeutics reports initial data from RT-114 study

2026-07-15T12:40:48.000Z - 2 months ago

Rani Therapeutics reports initial data from RT-114 study


Rani Therapeutics appoints Nicholas Maestas as CFO

2026-06-29T12:20:41.000Z - 2 months ago

Rani Therapeutics appoints Nicholas Maestas as CFO

TPST


Rani Therapeutics Holdings Transcript: AGM 2026

May 28, 2026, 11:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Transcript: AGM 2026


Rani Therapeutics Holdings Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Quarterly report: Q1 2026


Rani Therapeutics Holdings Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Earnings release: Q1 2026


Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing


Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025


Rani Therapeutics Holdings Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Annual report: Q4 2025


Rani Therapeutics Holdings Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings release: Q4 2025


Rani Therapeutics promotes Javadi to Chief Technical Officer

2026-01-28T12:15:42.000Z - 7 months ago

Rani Therapeutics promotes Javadi to Chief Technical Officer


Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

2026-01-08T12:10:14.000Z - 8 months ago

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill


Rani Therapeutics Holdings Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Earnings release: Q3 2025


Rani Therapeutics Holdings Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Quarterly report: Q3 2025


Rani Therapeutics Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q2 2025


Rani Therapeutics Holdings Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q2 2025


Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai


Rani Therapeutics Holdings Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q1 2025


Rani Therapeutics Holdings Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q1 2025


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024


Rani Therapeutics Holdings Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Annual report: Q4 2024


Rani Therapeutics Holdings Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q4 2024


Rani Therapeutics Holdings Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q3 2024


Rani Therapeutics Holdings Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Earnings release: Q3 2024


Rani Therapeutics Holdings Quarterly report: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2024


Rani Therapeutics Holdings Earnings release: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q2 2024


Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in August Investor Conferences


Rani Therapeutics Holdings Transcript: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Investor Update


Rani Therapeutics Holdings Press release: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Press release: Investor Update


Rani Therapeutics Holdings Slides: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Slides: Investor Update


Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences


Rani Therapeutics Holdings Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q1 2024


Rani Therapeutics Holdings Earnings release: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q1 2024


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023


Rani Therapeutics Holdings Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Annual report: Q4 2023


Rani Therapeutics Holdings Earnings release: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q4 2023


Rani Therapeutics Holdings Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q3 2023


APRadek
APRadek Sep. 13 at 3:05 PM
$RANI if Form 13G appears following completed and upcoming meetings then ill be adding
0 · Reply
Mandalo
Mandalo Sep. 13 at 7:33 AM
$RANI Form 3 filed, Michelle Gilson has. ​Exercise price: $7.46, it is. ​Holdings: 12,500 option shares, disclosed. ​Director role: Joined the board, she did. Very interesting it is !
3 · Reply
Mandalo
Mandalo Sep. 13 at 7:23 AM
$RANI Connected, Jesper Høiland is. Former Novo Nordisk chief, he was. To Rani Therapeutics, his wisdom now he brings. ​To Rani Therapeutics, joined he has: Head of Strategy, he became. ​From Novo Nordisk, he came: U.S. President, once he was. ​The bridge, he is: Oral RaniPill for obesity and diabetes, push forward he does!
0 · Reply
KaShing01
KaShing01 Sep. 12 at 4:48 PM
$RANI Showing sign of improvements……PT $7.20+
0 · Reply
Mandalo
Mandalo Sep. 12 at 3:23 AM
$RANI In five years, explode Rani Therapeutics' valuation could, hmm. ​From a small $120 million micro-cap today, to a $2.X billion or $5+ billion powerhouse, grow it might. Yes, hrrmm: ​Today small, it is: A cap of $120 million, a mere micro-cap, Rani currently remains. ​The future, bright it shines: In half a decade, transform it will. ​Mighty power, it shall gain: Two billion, five billion, or more, its worth shall become! ​Patience you must have, if market fortunes you seek, yes!
1 · Reply
wavw
wavw Sep. 11 at 7:46 PM
$RANI No one is selling. Shorts need 8 million shares to cover. Some good news will trigger above $5 easily.
1 · Reply
KaShing01
KaShing01 Sep. 11 at 4:37 PM
0 · Reply
French_Vibe
French_Vibe Sep. 11 at 2:27 PM
$RANI could be a good target for a buyout by $HALO IMHO
2 · Reply
OTC85
OTC85 Sep. 11 at 1:35 AM
$RANI https://x.com/ElFonzieMero/status/2091752684432822496
0 · Reply
OTC85
OTC85 Sep. 11 at 1:34 AM
$RANI $ADTX . . https://x.com/ElFonzieMero/status/2091752681102569808
1 · Reply
wavw
wavw Sep. 9 at 8:23 PM
$RANI fell on low volume…
0 · Reply
KaShing01
KaShing01 Sep. 9 at 2:48 PM
$RANI increase
0 · Reply
CallMeMyBeer
CallMeMyBeer Sep. 9 at 1:26 PM
$RANI nobody cares about a pill that stabs your insides 😏
1 · Reply
wavw
wavw Sep. 8 at 4:34 PM
$RANI got stuck with some penny traders…
1 · Reply
Mandalo
Mandalo Sep. 8 at 10:18 AM
$RANI Closing, the early bird discount is, feel it I do. ​The Warning: Hesitate too long, you must not. Once the moment passes, the lower price, gone it will be. ​The Action: Decide now, you should. Do or do not, there is no try!
0 · Reply
KaShing01
KaShing01 Sep. 8 at 3:30 AM
$RANI $1.15+
0 · Reply
Jack696
Jack696 Sep. 5 at 6:15 PM
$RANI Creeping up slooowly but surely. It has about a month to reach and maintian $1+
0 · Reply
wavw
wavw Sep. 4 at 8:06 PM
0 · Reply
Makingmillions192
Makingmillions192 Sep. 4 at 2:34 PM
$LEXX The CEO dropped a HUGE hidden nugget in the latest PR that the market completely glossed over in my opinion. He explicitly confirmed LEXX will announce their 2027 R&D plans in the coming months. Why does this matter? 👇 1️⃣ Commercial Deal Negotiations: Companies don't map out multi-year trial pipelines in a vacuum—they align them with active out-licensing & co-development partner talks! 🤝 They are actively working to secure a commercial deal imo. 2️⃣ Perpetual "Cash Loop": Recycling the $2.6M USD rebate back into Australian trials means ~43.5% non-dilutive refunds ON REPEAT to fund 2027 R&D! 💰 3️⃣ Maximum Partner Leverage: Proves to PharmaCO & PegBio that Lexaria isn’t waiting around. The platform moves forward with or without them! 💪 With Human Study #7 GLP-1 readout imminent the setup is absolute fire! 🔥 $LLY $NVO $RANI $VIK #Biotech #GLP1 https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-receives-usd2.6-million-tax-rebate-payment-1214902
0 · Reply
wavw
wavw Sep. 4 at 1:46 PM
$RANI not even 10k volume at opening. No one is selling!!! Obviously no one is buying at higher price.
0 · Reply
Mandalo
Mandalo Sep. 3 at 9:19 PM
$RANI Why it takes time? Building and expanding the RaniPill platform takes time primarily because it requires custom, automated manufacturing for micro-robotics and complex combination-product engineering. ​Key factors slowing platform development include: ​Custom Automation: Standard pharma machinery cannot build microscopic mechanical pills. Custom manufacturing lines must be designed, built, and validated under strict GMP standards. ​Micro-Engineering Precision: Designing swallowable capsules with reliable self-actuating balloons and biodegradable needles demands exhaustive iterations to ensure 100% safety and consistency. ​Payload Adaptation: Expanding from RaniPill GO to High Capacity (HC) requires re-engineering internal mechanics while keeping the capsule small enough to swallow. ​Regulatory Rigor: As a drug-device combination, every platform iteration undergoes intense FDA scrutiny for both mechanical safety and drug stability. 😇🤑👍
0 · Reply
wavw
wavw Sep. 3 at 8:22 PM
$RANI am bit surprised ..even after a year Chugai didn’t release any payment apart from initial $10 million.
2 · Reply